TY - JOUR
T1 - Folding-function relationship of the most common cystic fibrosis-causing CFTR conductance mutants
AU - Van Willigen, Marcel
AU - Vonk, Annelotte M.
AU - Yeoh, Hui Ying
AU - Kruisselbrink, Evelien
AU - Kleizen, Bertrand
AU - Van Der Ent, Cornelis K.
AU - Egmond, Maarten R.
AU - De Jonge, Hugo R.
AU - Braakman, Ineke
AU - Beekman, Jeffrey M.
AU - Van Der Sluijs, Peter
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Cystic fibrosis is caused by mutations in the CFTR gene, which are subdivided into six classes. Mutants of classes III and IV reach the cell surface but have limited function. Most class-III and class-IV mutants respond well to the recently approved potentiator VX-770, which opens the channel. We here revisited function and folding of some class-IV mutants and discovered that R347P is the only one that leads to major defects in folding. By this criterion and by its functional response to corrector drug VX-809, R347P qualifies also as a class-II mutation. Other class-IV mutants folded like wild-type CFTR and responded similarly to VX-809, demonstrating how function and folding are connected. Studies on both types of defects complement each other in understanding how compounds improve mutant CFTR function. This provides an attractive unbiased approach for characterizing mode of action of novel therapeutic compounds and helps address which drugs are efficacious for each cystic fibrosis disease variant.
AB - Cystic fibrosis is caused by mutations in the CFTR gene, which are subdivided into six classes. Mutants of classes III and IV reach the cell surface but have limited function. Most class-III and class-IV mutants respond well to the recently approved potentiator VX-770, which opens the channel. We here revisited function and folding of some class-IV mutants and discovered that R347P is the only one that leads to major defects in folding. By this criterion and by its functional response to corrector drug VX-809, R347P qualifies also as a class-II mutation. Other class-IV mutants folded like wild-type CFTR and responded similarly to VX-809, demonstrating how function and folding are connected. Studies on both types of defects complement each other in understanding how compounds improve mutant CFTR function. This provides an attractive unbiased approach for characterizing mode of action of novel therapeutic compounds and helps address which drugs are efficacious for each cystic fibrosis disease variant.
UR - http://www.scopus.com/inward/record.url?scp=85060780432&partnerID=8YFLogxK
U2 - 10.26508/lsa.201800172
DO - 10.26508/lsa.201800172
M3 - Article
C2 - 30659068
AN - SCOPUS:85060780432
VL - 2
JO - Life Science Alliance
JF - Life Science Alliance
IS - 1
M1 - e201800172
ER -